Product Description
| Cat Number | KS-240 |
|---|---|
| Category | Peptide |
| Pack Size | 1 mg |
| Description | Targets PI3K/AKT/mTOR signaling |
| Modification | None |
| Purity | >98% by hplc |
| Biomarker Target | Kinases,Tachykinin receptors |
| Sequence Three Letter Code | H-Asp-Pro-Pro-Ser-Asp-Asp-Glu-Phe-Val-Ser-Leu-Met-OH |
| Molecular Formula | C58H86N12O23S |
| Sl Sequence | DPPSDDEFVSLM |
| Appearance | Freeze dried solid |
| Storage | Store dry, frozen and in the dark |
| References |
Moral-Sanz et al (2021) ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations. Toxins (Basel) 13(2) 146 PMID: 33672955Moral-Sanz (2022) The structural conformation of the tachykinin domain drives the anti-tumoural activity of an octopus peptide in melanoma BRAFV600E. Br J Pharmacol. 179(20) 4878 PMID: 35818835IUPHAR-BPS Guide to pharmacology - Octpep-1 Related areasAll peptides >All kinase modulators >All cancer research categories > |
| Note | The product is for research use only |
Share Item: